Get the Stockscreener App
927.03
2.55%
23.04
After Hours:
925.92
-1.11
-0.12%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $927.03, with a volume of 3.24M.
It is up +2.55% in the last 24 hours and down -0.36% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$903.99
Open:
$917.8
24h Volume:
3.24M
Relative Volume:
1.04
Market Cap:
$828.17B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
41.04
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-1.32%
1M Performance:
-0.36%
6M Performance:
+15.47%
1Y Performance:
+10.37%
1-Day Range:
$917.80
$929.99
1-Week Range:
$888.03
$945.90
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
927.03 | 807.59B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.18 | 564.92B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
208.38 | 369.65B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.80 | 310.90B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.07 | 285.17B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Is This the Biggest Game-Changer in Lilly's 150-Year History? - AOL.com
Lilly weight-loss pill Foundayo shows strong first-week demand - USA Today
Potential Market Challenges for Eli Lilly's Weight Loss Drugs (L - GuruFocus
Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces Bankruptcy - Benzinga
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,163 - Moomoo
Eli Lilly Going Nuclear - WIBC 93.1 FM
Lilly's Unified Mindset For A Global Parenteral and Device Manufacturing Network - Bioprocess Online
Eli Lilly (LLY) Study Shows Tirzepatide Leads to Greater Weight Loss Impacting Lean Mass - GuruFocus
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake - Benzinga
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market - Pharmaceutical Executive
Eli Lilly’s (LLY) Weight-Loss Pill Prescribed Nearly 1,400 Time in Its First Week - TipRanks
Truist reiterates Eli Lilly stock rating on positive trial data - Investing.com
Eli Lilly's Foundayo And Novo Nordisk’s Wegovy – A Look At Some Key Highlights - Stocktwits
Eli Lilly and Company (LLY) Price Target Increased At Morgan Stanley on Updated Biopharma Model Assumptions - Yahoo Finance
Lilly's obesity pill draws 1,390 US prescriptions in launch week - Reuters
Guggenheim reiterates Eli Lilly stock rating on positive trial data - Investing.com
Indiana and Eli Lilly to Collaborate on Nuclear Energy Solutions - wwbl.com
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,163 to $1,350 - 富途牛牛
Eli Lilly (LLY) Stock Rises 3% on Foundayo Prescription Data and Heart Study - CoinCentral
Lilly's New GLP-1 Pill Is off to a 'Robust' Start - Moomoo
Novo may have muscle advantage over Lilly in weight-loss race: preprint - BioSpace
Eli Lilly (LLY) Sees Early Success with Foundayo Prescriptions - GuruFocus
Indiana, Eli Lilly to partner to bring nuclear power to the state - MSN
Lilly weight loss pill prescriptions said to near 1,400 in first week of launch - Seeking Alpha
Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week - marketscreener.com
5 notable pharma CEO pay hikes in 2025 - BioPharma Dive
Eli Lilly to submit diabetes pill for US approval this quarter - medwatch.com
Eli Lilly vs. Novo Nordisk: Which Stock Is the Better Buy? - HarianBasis.co
Braun signs nuclear energy-related letter of intent with Eli Lilly and Company - MSN
Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win - Law360
Lilly to work with Gov. Braun's administration to explore nuclear energy solutions - The Journal Gazette
FDA asks drug manufacturer for more safety data on Foundayo GLP-1 - USA Today
Novo Nordisk Brings in OpenAI as NVO Stock Sits Near 52-Week Lows Amid Generic Pressure, Eli Lilly Competition - foreignpolicyjournal.com
Eli Lilly's Oral Drug Clears CV Test, Hims Surges 14% - Gotrade
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment - WSJ
CrossBridge Bio: Up To $300 Million Acquisition By Eli Lilly To Advance Dual-Payload ADC Cancer Therapies - Pulse 2.0
Eli Lilly acquires Houston biotech startup for $300M - Houston Chronicle
Lilly Reports 57% Lower Death Risk in Foundayo Cardiovascular St - GuruFocus
Lilly’s Foundayo lowers heart attack, stroke risk in study - USA Today
Lilly Clears Cardiovascular Overhang on Foundayo - GuruFocus
ATUM Names Genentech and Eli Lilly Veteran Gavin Barnard as Chief Scientific Officer - citybiz
Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds - Reuters
Lilly eyes diabetes expansion for Foundayo after Phase III CV outcomes trial - FirstWord Pharma
US appeals court revives Teva lawsuit against Eli Lilly over migraine drug - Reuters
Braun administration, Eli Lilly to collaborate on nuclear power development - Indianapolis Business Journal
Leerink reiterates Eli Lilly stock rating on diabetes drug results - Investing.com
Lilly’s new obesity pill passes heart safety test in diabetes - BioPharma Dive
Is This $6.3 Billion Deal a Game Changer for Eli Lilly? - AOL.com
Eli Lilly (LLY) Stock Rises as Foundayo Obesity Pill Cuts Heart Death Risk by Over Half - CoinCentral
Gov. Mike Braun Signs Nuclear Energy Letter Of Intent With Eli Lilly And Company - InkFreeNews.com
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request - Pharmaceutical Executive
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):